Table 3 Multivariate HRs and 95% CIs for risk of BC death following local recurrence by surgery type

From: Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time

 

Mastectomy

Breast conservation

 

BC death ( N =198)

No BC death ( N =55)

HR

95% CI

BC death ( N =167)

No BC death ( N =146)

HR

95% CI

Mean age at diagnosis (years)

⩽49

49 (27.22)

12 (23.53)

1.00

Ref.

63 (39.38)

48 (34.78)

1.00

Ref.

50–59

67 (37.22)

18 (35.29)

0.95

0.66–1.38

39 (24.38)

33 (23.91)

1.18

0.76–1.81

60–69

46 (25.56)

14 (27.45)

0.65

0.43–0.98

19 (11.88)

18 (13.04)

1.52

0.84–2.74

⩾70

18 (10.00)

7 (13.73)

1.34

0.74–2.41

39 (24.38)

39 (28.26)

2.89

0.93–8.93

Invasive grade

Grade 1

9 (5.56)

7 (18.42)

1.00

Ref.

4 (2.86)

18 (15.13)

1.00

Ref.

Grade 2

71 (43.83)

15 (39.47)

2.76

1.36–5.59

68 (48.57)

64 (53.78)

4.49

1.40–14.42

Grade 3

82 (50.62)

16 (42.11)

3.90

1.89–8.02

67 (47.86)

36 (30.25)

7.21

2.23–23.36

Missing

0 (0.00)

0 (0.00)

—

—

1 (0.71)

1 (0.84)

—

—

No. of positive lymph nodes

0

37 (18.69)

22 (40.00)

1.00

Ref.

44 (26.35)

67 (45.89)

1.00

Ref.

1–3

54 (27.27)

16 (29.09)

1.21

0.76–1.92

52 (31.14)

36 (24.66)

2.01

1.29–3.13

4–10

45 (22.73)

6 (10.91)

1.96

1.19–3.23

15 (8.98)

3 (2.05)

3.23

1.72–6.08

>10

47 (23.74)

4 (7.27)

2.41

1.44–4.05

26 (15.57)

3 (2.05)

3.69

2.16–6.29

Missing

15 (7.58)

7 (12.73)

1.24

0.60–2.55

30 (17.96)

37 (25.34)

1.68

0.98–2.90

Chemotherapy

No

148 (74.75)

45 (81.82)

1.00

Ref.

132 (79.04)

124 (84.93)

1.00

Ref.

Yes

50 (25.25)

10 (18.18)

1.40

0.98–1.99

35 (20.96)

22 (15.07)

1.51

0.91–2.50

Radiotherapy

No

177 (89.39)

48 (87.27)

1.00

Ref.

37 (22.16)

41 (28.08)

1.00

Ref.

Yes

21 (10.61)

7 (12.73)

1.39

0.77–2.50

130 (77.84)

105 (71.92)

1.30

0.69–2.46

Endocrine therapy

No

162 (81.82)

43 (78.18)

1.00

Ref.

102 (61.08)

72 (49.32)

1.00

Ref.

Yes

36 (18.18)

12 (21.82)

0.70

0.43–1.15

65 (38.92)

74 (50.68)

0.65

0.38–1.12

Time to LR (years)

Mean (s.d.)

2.75 (3.08)

5.64 (4.76)

0.81

0.76–0.86

3.74 (3.09)

6.47 (5.69)

0.80

0.75–0.86

<0.5

22 (11.11)

2 (3.64)

24.92

10.29–60.38

7 (4.19)

3 (2.05)

8.78

2.59–29.73

0.5–1

41 (20.71)

6 (10.91)

11.96

5.28–27.13

26 (15.57)

12 (8.22)

29.21

12.34–69.11

1–2

51 (25.76)

10 (18.18)

8.03

3.67–17.57

29 (17.37)

18 (12.33)

7.21

3.33–15.61

2–5

56 (28.28)

13 (23.64)

5.42

2.51–11.69

57 (34.13)

48 (32.88)

3.93

1.94–7.98

5–10

19 (9.60)

12 (21.82)

2.71

1.16–6.37

38 (22.75)

34 (23.39)

2.80

1.33–5.86

>10

9 (4.55)

12 (21.82)

1.00

(ref)

10 (5.99)

31 (21.23)

1.00

(ref)

Tumour side

Left

97 (48.99)

27 (49.09)

1.00

Ref.

72 (43.11)

69 (47.26)

1.00

Ref.

Right

86 (43.43)

21 (38.18)

1.26

0.92–1.74

89 (53.29)

64 (43.84)

1.19

0.83–1.68

Unknown

15 (7.58)

7 (12.73)

3.24

0.43–24.51

6 (3.59)

13 (8.90)

20.40

2.52–164.98

Menopausal status

Pre

65 (32.83)

15 (27.27)

1.00

Ref.

70 (41.92)

59 (40.69)

1.00

Ref.

Peri

28 (14.14)

8 (14.55)

1.34

0.80–2.24

11 (6.59)

9 (6.21)

1.50

0.74–3.03

Post

105 (53.03)

32 (58.18)

1.26

0.69–2.32

86 (51.50)

77 (53.10)

1.57

0.83–2.97

Family history

First degree

23 (11.62)

11 (20.00)

1.00

Ref.

12 (7.19)

12 (8.22)

1.00

Ref.

Second degree

19 (9.60)

5 (9.09)

2.59

1.27–5.27

5 (2.99)

11 (7.53)

0.71

0.24–2.09

None

149 (75.25)

34 (61.82)

1.77

1.11–2.82

137 (82.04)

105 (71.92)

1.00

0.53–1.90

First and second degree

3 (1.52)

3 (5.45)

1.23

0.35–4.26

6 (3.59)

3 (2.05)

0.56

0.16–1.95

Missing

4 (2.02)

2 (3.64)

9.58

2.91–31.48

7 (4.19)

15 (10.27)

1.06

0.30–3.73

No.of pregnancies

0

46 (25.00)

11 (21.57)

1.00

Ref.

28 (19.86)

25 (22.73)

1.00

Ref.

1–2

84 (45.65)

24 (47.06)

0.67

0.46–0.98

68 (48.23)

40 (36.36)

0.95

0.62–1.46

3–4

44 (23.91)

11 (21.57)

0.75

0.48–1.17

35 (24.82)

28 (25.45)

0.69

0.40–1.20

>4

10 (5.43)

4 (7.84)

0.71

0.34–1.48

10 (7.09)

16 (14.55)

0.55

0.27–1.12

Missing

0 (0.00)

1 (1.96)

—

—

0 (0.00)

1 (0.91)

—

—

Tumour size (cm)

<2

20 (10.10)

5 (9.09)

1.00

Ref.

27 (16.17)

28 (19.18)

1.00

Ref.

2–3

46 (23.23)

15 (27.27)

1.11

0.58–2.11

56 (33.53)

55 (37.67)

0.90

0.53–1.55

>3

132 (66.67)

35 (63.64)

1.34

0.74–2.42

84 (50.30)

63 (43.15)

1.15

0.69–1.90

Invasive type

Ductal Not otherwise Specified

154 (77.78)

34 (61.82)

1.00

Ref.

141 (84.43)

116 (79.45)

1.00

Ref.

lobular

26 (13.13)

14 (25.45)

0.62

0.30–1.27

15 (8.98)

12 (8.22)

0.50

0.20–1.25

Other

1 (0.51)

0 (0.00)

8.87

1.09–72.42

3 (1.80)

2 (1.37)

3.35

0.35–32.17

Missing

17 (8.59)

7 (12.73)

2.19

0.43–11.18

8 (4.79)

16 (10.96)

0.69

0.17–2.79

Oestrogen receptor status

Negative

71 (35.86)

14 (25.45)

1.00

Ref.

62 (37.13)

27 (18.49)

1.00

Ref.

Positive

110 (55.56)

31 (56.36)

0.79

0.57–1.09

97 (58.08)

101 (69.18)

0.54

0.38–0.78

Missing

17 (8.59)

10 (18.18)

0.31

0.08–1.29

8 (4.79)

18 (12.33)

0.63

0.19–2.08

Progesterone receptor status

Negative

108 (54.55)

21 (38.13)

1.00

Ref.

86 (51.50)

49 (33.56)

1.00

Ref.

Positive

67 (33.84)

21 (38.13)

0.78

0.56–1.09

71 (42.51)

79 (54.11)

0.63

0.44–0.91

Missing

23 (11.62)

13 (23.64)

0.45

0.21–0.99

10 (5.99)

18 (12.33)

1.01

0.36–2.87

HER2-status

Negative

75 (37.88)

16 (29.09)

1.00

Ref.

79 (47.31)

57 (39.04)

1.00

Ref.

Positive

30 (15.15)

4 (7.27)

1.31

0.83–2.07

26 (15.57)

12 (8.22)

1.37

0.83–2.27

Missing

93 (46.97)

35 (63.64)

0.59

0.41–0.84

62 (37.13)

77 (52.74)

0.69

0.47–1.03

  1. Abbreviations: BC=breast cancer; CI, confidence interval; HR=hazard ratios; LR=locoregional recurrence; Ref.=reference.
  2. —, No estimate because of small numbers.
  3. Models were adjusted for age, tumour grade, pathological nodal stage, treatment methods of the initial cancer (except where stated), and locoregional recurrence as a time-dependent variable. The upper (above part heading ‘Tumour side’) section of the table represents a multivariable model including only covariates listed within this section. The following (from part heading ‘Tumour side’) section represents models adjusted for all aforementioned variables.
Back to article page